

INNOVA CAPTAB LIMITED
1281/1, Hilltop Industrial Estate, Near
EPIP, Phase-I, Jharmajri, Baddi, Dist.
Solan (H.P.)-173205 India.
Phone: +91-1795-650820



February 05, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('SEBI LODR Regulations'), we are enclosing herewith the Press Release issued by the Company on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024.

The Press Release is available on the website of the Company at www.innovacaptab.com

This is for your information and record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

Neeharika Shukla
Company Secretary & Compliance Officer
Membership No.: A42724

Encl.: As above

INNOVA CAPTAB LIMITED

Press Release

Performance Review of Q3 and 9M FY25

Innova Captab Limited reported healthy results for Q3 FY25, with Revenue from Operations at ₹ 316.5 crores and Profit After Tax (PAT) at ₹ 34.2 crores

Registered YoY Revenue growth of 4.6% and PAT growth of 36.3%

Mumbai 5th February 2024: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading integrated pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its financial results for the quarter and nine months ending December 31st, 2024.

Key Highlights

Q3 FY25 vs Q3 FY24

- Revenue from Operations was ₹ **316.5 crores** in the quarter vs ₹ **302.5 crores** last year, registering growth of **4.6%**
- EBITDA grew to ₹ **50.9 crores** vs ₹ **46.9 crores** last year. EBITDA Margins also improved to **16.1%** vs **15.5%** in Q3 FY24
- Profit after Tax improved significantly to ₹ **34.2 crores** vs ₹ **25.1 crores** (YoY growth of **36.3%**). PAT Margins improved to **10.8%** from **8.3%**

9M FY25 vs 9M FY24

- Revenue from Operations grew **13.5%** to ₹ **928.9 crores** vs ₹ **818.7 crores** during same period in the previous year
- EBITDA increased to ₹ **147.1 crores** vs ₹ **123.2 crores** (YoY improvement of **19.4%**). EBITDA margins improved by **80 bps** to **15.8%**
- Profit after Tax grew by **50.5%** to ₹ **98.7 crores** vs ₹ **65.6 crores** in 9M FY24. PAT Margin increased to **10.6%** from **8.0%**

Commenting on the results, **Mr. Vinay Lohariwala, Managing Director – Innova Captab Limited** said “We are delighted to report a healthy performance in Q3 and 9M FY25, driven by robust resilience in our core business operations and strategic advancements. Our revenue from operations registered YoY growth of 4.6% in Q3 FY25 and of 13.5% in 9M FY25. PAT demonstrated strong surge of 36.3% in Q3 FY25 and of 50.5% in 9M FY25.

Key highlight of the quarter was the successful launch of operations at our new Kathua, Jammu facility, where we commenced commercial production on January 14, 2025. This milestone represents a pivotal moment in our growth trajectory, bolstering both our production capacity and our ability to meet the evolving demands of our customers. This expansion is a cornerstone of our long-term strategic vision, reinforcing our market position and laying the foundation for sustained, profitable growth. With the added advantage of incentives from the central government, we are optimistic about the positive impact on profitability from the Jammu operations.

As we look to the future, we are confident in the continued strength and resilience of our business. With a diversified portfolio and a steadfast commitment to long-term value creation, our teams are united in executing our strategic priorities. We are well-positioned for sustained growth and are excited to build on this momentum in the years ahead.”

Financial Performance

(amount in ₹ crores except otherwise mentioned)

Q3 FY25 vs Q3 FY24

Particulars	Q3 FY25	Q3 FY24	YoY Growth
Revenue from Operations	316.5	302.5	4.6%
EBITDA	50.9	46.9	8.5%
EBITDA Margin (%)	16.1%	15.5%	60 bps
Profit before Tax	45.6	35.2	29.5%
Profit after Tax	34.2	25.1	36.3%

9M FY25 vs 9M FY24

Particulars	9M FY25	9M FY24	YoY Growth
Revenue from Operations	928.9	818.7	13.5%
EBITDA	147.1	123.2	19.4%
EBITDA Margin (%)	15.8%	15.0%	80 bps
Profit before Tax	131.7	90.0	46.3%
Profit after Tax	98.7	65.6	50.5%

About Innova Captab Limited

Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is an integrated pharmaceutical company in India with presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) segment, the company provides over 2,900 formulations to more than 190 pharmaceutical partners, including 14 of the top 15 companies in the Indian pharmaceuticals market. Innova's domestic branded generics business reaches 150,000 touchpoints, offering a diverse portfolio of over 600+ products. The company exports its finished formulations to more than 25 countries worldwide and operates four state-of-the-art manufacturing facilities accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA among others.

Additionally, Innova has expanded its capabilities with a greenfield project of a multi-dosage plant in Jammu, India which consists of 4 blocks – Cephalosporin, Penum, Penicillin and General. Together with this, the company now has total of 9 manufacturing blocks. Along with this, the company is also focussed on its R&D endeavours and is establishing a new R&D facility in Panchkula, Haryana in addition to the existing one in Baddi.

For more details, please visit www.innovacaptab.com

For more information, please contact:

Mr. Lokesh Bhasin / Ayush Kumar Garg

Email: investors@innovacaptab.com / ayush.garg@innovacaptab.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.